48 related articles for article (PubMed ID: 21635884)
1. Oral administration of the thrombin receptor antagonist E5555 (atopaxar) attenuates intimal thickening following balloon injury in rats.
Kogushi M; Matsuoka T; Kuramochi H; Murakami K; Kawata T; Kimura A; Chiba K; Musha T; Suzuki S; Kawahara T; Kajiwara A; Hishinuma I
Eur J Pharmacol; 2011 Sep; 666(1-3):158-64. PubMed ID: 21635884
[TBL] [Abstract][Full Text] [Related]
2. Elevated plasma levels of factor VIII enhance arterial thrombus formation on erosive smooth muscle cell-rich neointima but not normal intima in rabbits.
Sugita C; Maekawa K; Gi T; Oguri N; Nakamura E; Furukoji E; Azuma M; Asada Y; Yamashita A
Thromb Res; 2024 Jun; 238():185-196. PubMed ID: 38729030
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of anastomotic intimal hyperplasia by a synthetic nonsulphated heparin-mimicking compound.
Shargal Y; Viola N; Nagler A; Merin G; Schmidt A; Buddecke E; Ben-Sasson SA; Vlodavsky I
Exp Clin Cardiol; 2002; 7(2-3):73-9. PubMed ID: 19649227
[TBL] [Abstract][Full Text] [Related]
4. Lack of Endothelial Nitric Oxide Synthase Accelerates Ectopic Calcification in Uremic Mice Fed an Adenine and High Phosphorus Diet.
Oe Y; Mitsui S; Sato E; Shibata N; Kisu K; Sekimoto A; Miyazaki M; Sato H; Ito S; Takahashi N
Am J Pathol; 2021 Feb; 191(2):283-293. PubMed ID: 33159888
[TBL] [Abstract][Full Text] [Related]
5. Glomerular Injury Is Exacerbated in Lupus-Prone MRL/lpr Mice Treated with a Protease-Activated Receptor 2 Antagonist.
Itto R; Oe Y; Imaruoka K; Sato E; Sekimoto A; Yamakage S; Kumakura S; Sato H; Ito S; Takahashi N
Tohoku J Exp Med; 2019 Oct; 249(2):127-133. PubMed ID: 31666446
[TBL] [Abstract][Full Text] [Related]
6. Protease-activated receptor 2 exacerbates cisplatin-induced nephrotoxicity.
Watanabe M; Oe Y; Sato E; Sekimoto A; Sato H; Ito S; Takahashi N
Am J Physiol Renal Physiol; 2019 Apr; 316(4):F654-F659. PubMed ID: 30672316
[TBL] [Abstract][Full Text] [Related]
7. Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases.
Posma JJ; Grover SP; Hisada Y; Owens AP; Antoniak S; Spronk HM; Mackman N
Arterioscler Thromb Vasc Biol; 2019 Jan; 39(1):13-24. PubMed ID: 30580574
[TBL] [Abstract][Full Text] [Related]
8. Homeostatic effects of coagulation protease-dependent signaling and protease activated receptors.
Isermann B
J Thromb Haemost; 2017 Jul; 15(7):1273-1284. PubMed ID: 28671351
[TBL] [Abstract][Full Text] [Related]
9. Coagulation Factor Xa and Protease-Activated Receptor 2 as Novel Therapeutic Targets for Diabetic Nephropathy.
Oe Y; Hayashi S; Fushima T; Sato E; Kisu K; Sato H; Ito S; Takahashi N
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1525-33. PubMed ID: 27283743
[TBL] [Abstract][Full Text] [Related]
10. Protease-Activated Receptors (PARs): Biology and Therapeutic Potential in Perioperative Stroke.
Mavridis T; Choratta T; Papadopoulou A; Sawafta A; Archontakis-Barakakis P; Laou E; Sakellakis M; Chalkias A
Transl Stroke Res; 2024 Feb; ():. PubMed ID: 38326662
[TBL] [Abstract][Full Text] [Related]
11. Dual blockade of protease-activated receptor 1 and 2 additively ameliorates diabetic kidney disease.
Mitsui S; Oe Y; Sekimoto A; Sato E; Hashizume Y; Yamakage S; Kumakura S; Sato H; Ito S; Takahashi N
Am J Physiol Renal Physiol; 2020 May; 318(5):F1067-F1073. PubMed ID: 32200667
[TBL] [Abstract][Full Text] [Related]
12. Recent Progress in Research on the Pathogenesis of Pulmonary Thromboembolism: An Old Story with New Perspectives.
Yan C; Wang X; Su H; Ying K
Biomed Res Int; 2017; 2017():6516791. PubMed ID: 28484717
[TBL] [Abstract][Full Text] [Related]
13. Vein graft failure: from pathophysiology to clinical outcomes.
de Vries MR; Simons KH; Jukema JW; Braun J; Quax PH
Nat Rev Cardiol; 2016 Aug; 13(8):451-70. PubMed ID: 27194091
[TBL] [Abstract][Full Text] [Related]
14. Scoparone interferes with STAT3-induced proliferation of vascular smooth muscle cells.
Park S; Kim JK; Oh CJ; Choi SH; Jeon JH; Lee IK
Exp Mol Med; 2015 Mar; 47(3):e145. PubMed ID: 25744297
[TBL] [Abstract][Full Text] [Related]
15. Thrombin receptor antagonism in antiplatelet therapy.
Olivier C; Diehl P; Bode C; Moser M
Cardiol Ther; 2013 Jun; 2(1):57-68. PubMed ID: 25135289
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteases and PAR1 activation.
Austin KM; Covic L; Kuliopulos A
Blood; 2013 Jan; 121(3):431-9. PubMed ID: 23086754
[TBL] [Abstract][Full Text] [Related]
17. Promises of PAR-1 inhibition in acute coronary syndrome.
Leonardi S; Tricoci P; Mahaffey KW
Curr Cardiol Rep; 2012 Feb; 14(1):32-9. PubMed ID: 22160877
[TBL] [Abstract][Full Text] [Related]
18. Novel agents for anti-platelet therapy.
Ji X; Hou M
J Hematol Oncol; 2011 Nov; 4():44. PubMed ID: 22053759
[TBL] [Abstract][Full Text] [Related]
19. Exogenous thrombin delivery promotes collateral capillary arterialization and tissue reperfusion in the murine spinotrapezius muscle ischemia model.
Bruce AC; Peirce SM
Microcirculation; 2012 Feb; 19(2):143-54. PubMed ID: 21954923
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
